Halozyme Therapeutics (NASDAQ:HALO) Receives "Buy" Rating from HC Wainwright

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They currently have a $72.00 price target on the biopharmaceutical company's stock. HC Wainwright's target price indicates a potential upside of 28.62% from the stock's previous close.

A number of other research analysts have also weighed in on HALO. Leerink Partnrs lowered shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, May 13th. JPMorgan Chase & Co. lifted their price target on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. Leerink Partners lowered shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target on the stock. in a research note on Tuesday, May 13th. Benchmark lowered shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Finally, Morgan Stanley lowered shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and cut their price target for the company from $73.00 to $62.00 in a research note on Wednesday, May 14th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $61.90.

Halozyme Therapeutics Trading Up 2.3%

Halozyme Therapeutics stock traded up $1.25 during midday trading on Thursday, hitting $55.98. 2,233,873 shares of the stock were exchanged, compared to its average volume of 1,633,884. The company has a fifty day simple moving average of $58.91 and a two-hundred day simple moving average of $55.67. Halozyme Therapeutics has a 52 week low of $42.01 and a 52 week high of $70.51. The stock has a market capitalization of $6.90 billion, a PE ratio of 16.32, a P/E/G ratio of 0.42 and a beta of 1.26. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.13. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The business had revenue of $264.86 million for the quarter, compared to analyst estimates of $231.21 million. During the same quarter last year, the firm earned $0.79 EPS. Halozyme Therapeutics's quarterly revenue was up 35.2% compared to the same quarter last year. Equities research analysts anticipate that Halozyme Therapeutics will post 4.73 EPS for the current fiscal year.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total value of $293,450.00. Following the transaction, the director now directly owns 33,611 shares in the company, valued at $1,972,629.59. The trade was a 12.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders have sold 10,000 shares of company stock worth $597,151. Insiders own 2.90% of the company's stock.

Hedge Funds Weigh In On Halozyme Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of HALO. Isthmus Partners LLC lifted its position in Halozyme Therapeutics by 2.5% during the first quarter. Isthmus Partners LLC now owns 6,875 shares of the biopharmaceutical company's stock worth $439,000 after purchasing an additional 169 shares during the period. OneDigital Investment Advisors LLC lifted its position in Halozyme Therapeutics by 1.7% during the first quarter. OneDigital Investment Advisors LLC now owns 10,176 shares of the biopharmaceutical company's stock worth $649,000 after purchasing an additional 175 shares during the period. Park Place Capital Corp lifted its position in Halozyme Therapeutics by 20.1% during the first quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock worth $69,000 after purchasing an additional 182 shares during the period. Smartleaf Asset Management LLC lifted its position in Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 197 shares during the period. Finally, Xponance Inc. lifted its position in Halozyme Therapeutics by 1.1% during the first quarter. Xponance Inc. now owns 18,652 shares of the biopharmaceutical company's stock worth $1,190,000 after purchasing an additional 198 shares during the period. 97.79% of the stock is currently owned by institutional investors and hedge funds.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.